e-ILD: a fully automated, AI-powered solution for assessment of Interstitial Lung Disease (ILD)

There is a growing need for more accurate and reproducible assessment and quantification of Interstitial Lung Disease.

Brainomix’ e-ILD solution has been trained to characterize and quantify pulmonary fibrosis and other characteristics using thousands of cases from leading academic institutions.

Automated biomarkers such as those available through e-ILD have been shown to correlate with mortality, and to predict changes in FVC at earlier timepoints.

Desktop e-ILD Perspective

AI-powered biomarkers from e-ILD are available now for use in clinical trials, and can support:

Efficacy measurement as an adjunct to traditional functional measures such as FVC

Enrichment of trial cohort with progressive fibrosis phenotype

Reduced sample sizes and faster trial execution

Contact us today

Speak with us to learn how to integrate our ILD biomarkers into your clinical trials and clinical research.

Hear from our valued partners and collaborators

Our Partners

Leave Your Legacy Portuguese Logo
Boehringer Ingelheim Logo
Nvidia Logo
GE Healthcare
Wallaby Logo